Restricted accessResearch articleFirst published online 2010-08
Review of the Use of the Glutamate Antagonist Riluzole in Psychiatric Disorders and a Description of Recent Use in Childhood Obsessive-Compulsive Disorder
The antiglutamatergic drug riluzole (Rilutek®) is presently being used off label in the treatment of psychiatric conditions in adult patients and, increasingly, in children. This article briefly reviews the pharmacology of this drug and its current investigative and clinical uses and adverse effects. It also reports on our experience to date in the study of the drug in children, with emphasis on adverse effects noted so far in these younger patients.
Get full access to this article
View all access options for this article.
References
1.
AhnHS, ChoiJS, ChoiBH, KimMJ, RhieDJ, YoonSH, JoYH, KimMS, SungKW, HahnSJ. Inhibition of the cloned delayed rectifier K+ channels, Kv1.5 and Kv3.1, by riluzole. Neuroscience, 133:1007–1019. 2005.
2.
Ajroud-DrissS, SaeedM, KhanH, SiddiqueN, HungWY, SufitR, HellerS, ArmstrongJ, CaseyP, SiddiqueT, LukasTJ. Riluzole metabolism and CYP1A1/2 polymorphisms in patients with ALS. Amyotroph Lateral Scler, 8:305–09. 2007.
3.
AndersenV, SonneJ, AndersenM. Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999. Eur J Clin Pharmacol, 57:517–521. 2001.
4.
BanasrM, ChowdhuryGM, TerwilligerR, NewtonSS, DumanRS, BeharKL, SanacoraG. Glial pathology in an animal model of depression: Reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry, 15:501–511. 2010.
5.
BodnerT, JennerC, BenkeT, OberA, SeppiK, FleischhackerWW. Intoxication with riluzole in Huntington's disease. Neurology, 57:1141–1143. 2001.
6.
Borderias-ClauL, Garrapiz-LopezJ, Val-AdanP, Tordesillas-LiaC, Alcacera-LopezA, Bru-MartinJL. Strong suspicion of lung toxicity due to riluzole. Arch Bronconeumol, 42:42–44. 2006.
7.
BrunoR, VivierN, MontayG, Le LibouxA, PoweLK, DelumeauJC, RhodesGR. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. Clin Pharmacol Ther, 62:518–526. 1997.
8.
CassimanD, ThomeerM, VerbekenE, RobberechtW. Hypersensitivity pneumonitis possibly caused by riluzole therapy in ALS. Neurology, 61:1150–1151. 2003.
9.
ChenWC, ChengHH, HuangCJ, ChouCT, LiuSI, ChenIS, HsuSS, ChangHT, HuangJK, JanCR. Effect of riluzole on Ca2+ movement and cytotoxicity in Madin-Darby canine kidney cells. Hum Exp Toxicol, 25:461–469. 2006.
10.
CoricV, MilanovicS, WasylinkS, PatelP, MalisonR, KrystalJH. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl), 167:219–220. 2003.
CoricV, KelmendiB, PittengerC, WasylinkS, BlochMH, GreenJ. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with trichotillomania. J Clin Psychiatry, 68:170–171. 2007.
13.
DagciT, YilmazO, TaskiranD, PekerG. Neuroprotective agents: Is effective on toxicity in glial cells?Cell Mol Neurobiol, 27:171–177. 2007.
DuJ, SuzukiK, WeiY, WangY, BlumenthalR, ChenZ, FalkeC, ZarateCAJr., ManjiHK. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: Relationship to clinical effects in mood disorders. Neuropsychopharmacology, 32:793–802. 2006.
16.
FrizzoME, Dall'OnderLP, DalcinKB, SouzaDO. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol, 24:123–128. 2004.
17.
FumagalliE, BiginiP, BarberaS, De PaolaM, MenniniT. Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease. Exp Neurol, 198:114–128. 2006.
18.
FumagalliE, FunicelloM, RauenT, GobbiM, MenniniT. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur J Pharmacol, 578:171–176. 2008.
19.
GrantP, LougeeL, HirschtrittM, SwedoSE. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol, 17:761–767. 2007.
20.
GroeneveldGJ, van KanHJ, ToranoJS, VeldinkJH, GuchelaarHJ, WokkeJH, van den BergLH. Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS. J Neurol Sci, 191:121–125. 2001.
21.
GroeneveldGJ, Van KanHJ, KalmijnS, VeldinkJH, GuchelaarHJ, WokkeJH, Van den BergLH. Riluzole serum concentrations in patients with ALS: Associations with side effects and symptoms. Neurology, 61:1141–1143. 2003.
22.
GroeneveldGJ, van KanHJ, LieAHL, GuchelaarHJ, van den BergLH. An association study of riluzole serum concentration and survival and disease progression in patients with ALS. Clin Pharmacol Ther, 83:718–722. 2008.
23.
Habibi-AslB, HassanzadehK, CharkhpourM. Central administration of minocycline and riluzole prevents morphine-induced tolerance in rats. Anesth Analg, 109:936–942. 2009.
24.
HuangCS, SongJH, NagataK, YehJZ, NarahashiT. Effects of the neuroprotective agent riluzole on the high voltage-activated calcium channels of rat dorsal root ganglion neurons. J Pharmacol Exp Ther, 282:1280–1290. 1997.
25.
LacomblezL, BensimonG, LeighPN, GuilletP, MeiningerV. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet, 347:1425–1431. 1996.
26.
LacomblezL, BensimonG, LeighPN, DeboveC, BejuitR, TruffinetP, MeiningerV. Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord, 3:23–29. 2002.
27.
Le LibouxA, LefebvreP, Le RouxY, TruffinetP, AubeneauM, KirkesseliS, MontayG. Single- and multiple-dose pharmacokinetics of riluzole in white subjects. J Clin Pharmacol, 37:820–827. 1997.
28.
Le LibouxA, CachiaJP, KirkesseliS, GautierJY, GuimartC, MontayG, PeetersPA, GroenE, JonkmanJH, WemerJ. A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers. J Clin Pharmacol, 39:480–486. 1999.
29.
LogroscinoG, ZoccolellaS. Efficacy of riluzole: Who are the patients enrolled in the studies?Amyotroph Lateral Scler, 8:124–125author reply 1252007.
30.
MathewSJ, AmielJM, CoplanJD, FitterlingHA, SackeimHA, GormanJM. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry, 162:2379–2381. 2005.
31.
MathewSJ, MurroughJW, Aan Het RotM, CollinsKA, ReichDL, CharneyDS. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: A pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol, 13:71–82. 2010.
MilaneA, FernandezC, VautierS, BensimonG, MeiningerV, FarinottiR. Minocycline and riluzole brain disposition: Interactions with p-glycoprotein at the blood-brain barrier. J Neurochem, 103:164–173. 2007.
34.
MilaneA, VautierS, ChacunH, MeiningerV, BensimonG, FarinottiR, FernandezC. Interactions between riluzole and ABCG2/BCRP transporter. Neurosci Lett, 452:12–16. 2009.
35.
MillerRG, MitchellJD, LyonM, MooreDH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)Amyotroph Lateral Scler Other Motor Neuron Disord, 4:191–206. 2003.
36.
NorthWA, KhanAM, YamaseHT, SpornJR. Reversible granulocytopenia in association with riluzole therapy. Ann Pharmacother, 34:322–324. 2000.
37.
PittengerC, CoricV, BanasrM, BlochM, KrystalJH, SanacoraG. Riluzole in the treatment of mood and anxiety disorders. CNS Drugs, 22:761–786. 2008b.
38.
PittengerC, KelmendiB, WasylinkS, BlochMH, CoricV. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: A series of 13 cases, with long-term follow-up. J Clin Psychopharmacol, 28:363–367. 2008a.
39.
PittengerC, KrystalJH, CoricV. Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder. J Clin Psychiatry, 66:1492–1493. 2005.
RussmanBS, IannacconeST, SamahaFJ. A phase 1 trial of riluzole in spinal muscular atrophy. Arch Neurol, 60:1601–1603. 2003.
44.
SachseC, BrockmollerJ, BauerS, RootsI. Functional significance of a C–> A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol, 47:445–449. 1999.
45.
SanacoraG, KendellSF, LevinY, SimenAA, FentonLR, CoricV, KrystalJH. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry, 61:822–825. 2007.
46.
SanderinkGJ, BourniqueB, StevensJ, PetryM, MartinetM. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther, 282:1465–1472. 1997.
47.
SassoDA, KalanithiPS, TruebloodKV, PittengerC, KelmendiB, WayslinkS, MalisonRT, KrystalJH, CoricV. Beneficial effects of the glutamate-modulating agent riluzole on disordered eating and pathological skin-picking behaviors. J Clin Psychopharmacol, 26:685–687. 2006.
48.
ShortlandPJ, LeinsterVH, WhiteW, RobsonLG. Riluzole promotes cell survival and neurite outgrowth in rat sensory neurones in vitro. Eur J Neurosci, 24:3343–3353. 2006.
49.
SinghJ, ZarateCAJr., KrystalAD. Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine. Psychopharmacology (Berl), 173:227–228. 2004.
50.
SorensonEJ. An acute, life-threatening, hypersensitivity reaction to riluzole. Neurology, 67:2260–2261. 2006.
51.
UrbaniA, BelluzziO. Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci, 12:3567–3574. 2000.
52.
van KanHJ, SpieksmaM, GroeneveldGJ, ToranoJS, van den BergLH, GuchelaarHJ. A validated HPLC assay to monitor riluzole plasma or serum concentrations in patients with amyotrophic lateral sclerosis. Biomed Chromatogr, 18:723–726. 2004.
53.
van KanHJ, van den BergLH, GroeneveldGJ, van der StraatenRJ, van VughtPW, LieAHL, GuchelaarHJ. Pharmacokinetics of riluzole: Evidence for glucuronidation as a major metabolic pathway not associated with UGT1A1 genotype. Biopharm Drug Dispos, 29:139–144. 2008.
54.
ViallonA, PageY, BertrandJC. Methemoglobinemia due to riluzole. N Engl J Med, 343:665–666. 2000.
55.
WangSJ, WangKY, WangWC. Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes)Neuroscience, 125:191–201. 2004.
WokkeJH. Riluzole treatment in amyotrophic lateral sclerosis. Ned Tijdschr Geneeskd, 140:2265–2268. 1996.
58.
WoolfA, CarstairsSD, TanenDA. Riluzole-induced methemoglobinemia. Ann Emerg Med, 43:294. 2004.
59.
ZarateCAJr., PayneJL, QuirozJ, SpornJ, DenicoffKK, LuckenbaughD, CharneyDS, ManjiHK. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry, 161:171–174. 2004.
60.
ZarateCAJr., QuirozJA, SinghJB, DenicoffKD, De JesusG, LuckenbaughDA, CharneyDS, ManjiHK. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry, 57:430–432. 2005.
